niraparib
-
May 2, 2020
FDA Approves Niraparib for First-Line Maintenance of Advanced Ovarian Cancer Bookmark
George Lundberg, MDPress release from the U.S. Food and Drug Administration (FDA) curated by Editor in Chief George Lundberg, MD, who notes:
This FDA announcement is a welcome one for patients afflicted by epithelial ovarian cancer that has spread.
Go to full article published by the FDA.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
January 6, 2020
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer Bookmark
George Lundberg, MDResearch paper from The New England Journal of Medicine curated by Editor in Chief George Lundberg, MD, who notes:
These clinical trials results suggest that the drug niraparib is superior to platinum-based chemotherapy for people with newly diagnosed advanced ovarian cancer.
Go to full paper published in The New England Journal of Medicine.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
December 2, 2019
Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial Bookmark
George Lundberg, MDResearch paper from the Journal of Clinical Oncology curated by Editor in Chief George Lundberg, MD, who notes:
Niraparib substantially improves TWIST (time without symptoms or toxicity) over no treatment in recurrent epithelial ovarian cancers, even moreso if positive for gBRCAmu.
Go to full paper published in the Journal of Clinical Oncology.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
November 12, 2019
FDA Approves Test for Late-line HRD+ Ovarian Cancer Bookmark
George Lundberg, MDArticle from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes:
A new diagnostic test and new therapeutic drugs have received approval from the U.S. Food and Drug Administration (FDA) for certain advanced ovarian cancers, which are always difficult to treat.
Go to full article published by Cancer Network.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.